Filters: keyword is Binding [Clear All Filters]
- 2008
Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model,
J Pharmacol Exp Ther, vol. 324, no. 3, pp. 1234-42.
- 2007
Reproducible and time-dependent modification of serum protein binding in Wistar Kyoto rats,
J Pharmacol Toxicol Methods, vol. 56, no. 1, pp. 72-8.
- 2006
Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers,
Br J Pharmacol, vol. 148, no. 4, pp. 396-404.
- 2005
Brain penetration of synthetic adenosine A1 receptor agonists in situ: role of the rENT1 nucleoside transporter and binding to blood constituents,
Eur J Pharm Sci, vol. 24, no. 1, pp. 59-66.
Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo,
Pharmacol Ther, vol. 106, no. 1, pp. 1-18.
- 2004
Mechanism-based pharmacokinetic-pharmacodynamic modeling of 5-HT1A receptor agonists: estimation of in vivo affinity and intrinsic efficacy on body temperature in rats,
J Pharmacol Exp Ther, vol. 308, no. 3, pp. 1012-20.
- 2003
Dose-dependent EEG effects of zolpidem provide evidence for GABA(A) receptor subtype selectivity in vivo,
J Pharmacol Exp Ther, vol. 304, no. 3, pp. 1251-7.
- 2002
Mechanism-based pharmacokinetic-pharmacodynamic modeling of concentration-dependent hysteresis and biphasic electroencephalogram effects of alphaxalone in rats,
J Pharmacol Exp Ther, vol. 302, no. 3, pp. 1158-67.
Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol,
J Pharmacokinet Pharmacodyn, vol. 29, no. 3, pp. 235-50.
A competitive interaction model predicts the effect of WAY-100,635 on the time course of R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin-induced hypothermia,
J Pharmacol Exp Ther, vol. 300, no. 1, pp. 330-8.
- 1999
Multivariate quantitative structure-pharmacokinetic relationships (QSPKR) analysis of adenosine A1 receptor agonists in rat,
J Pharm Sci, vol. 88, no. 3, pp. 306-12.
A combined specific target site binding and pharmacokinetic model to explore the non-linear disposition of draflazine,
J Pharmacokinet Biopharm, vol. 27, no. 3, pp. 257-81.
- 1998
Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats,
J Pharmacol Exp Ther, vol. 284, no. 2, pp. 460-6.
- 1997
Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling,
Int J Clin Pharmacol Ther, vol. 35, no. 10, pp. 442-6.
Diclofenac plasma protein binding: PK-PD modelling in cardiac patients submitted to cardiopulmonary bypass,
Braz J Med Biol Res, vol. 30, no. 3, pp. 369-74.
Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates,
Br J Clin Pharmacol, vol. 43, no. 6, pp. 603-12.
Determination of dexmedetomidine in rat plasma by a sensitive [3H]clonidine radioreceptor assay,
J Pharm Sci, vol. 86, no. 7, pp. 822-6.
- 1995
Modelling of the pharmacodynamic interaction of an A1 adenosine receptor agonist and antagonist in vivo: N6-cyclopentyladenosine and 8-cyclopentyltheophylline,
Br J Pharmacol, vol. 115, no. 7, pp. 1253-9.
Pharmacokinetic-pharmacodynamic modelling of the cardiovascular effects of R- and S-N6-phenylisopropyladenosine in conscious normotensive rats,
J Pharmacol Exp Ther, vol. 273, no. 1, pp. 405-14.
- 1992
Pharmacokinetic considerations on Orgaran (Org 10172) therapy,
Haemostasis, vol. 22, no. 2, pp. 73-84.
- 1985
Kinetics of drug action in disease states. VI. Effect of experimental diabetes on phenobarbital concentrations in rats at onset of loss of righting reflex,
J Pharmacol Exp Ther, vol. 232, no. 2, pp. 435-8.
Kinetics of drug action in disease states. IV. Effect of pregnancy on phenobarbital concentrations at onset of loss of righting reflex in rats,
J Pharmacol Exp Ther, vol. 232, no. 2, pp. 426-9.



